Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
Status:
Terminated
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if Regadenoson may offer improved ease of use, single
dose administration, and better tolerance for testing for pulmonary hypertension than iNO.
You will be screened to make sure Regadenoson is safe for you with a clinical evaluation,
blood tests, and an ECG.